Staff augmentation is a common strategy deployed by companies to expand their workforce, especially in highly regulated industries such as Pharmaceuticals and Healthcare. However, there are many misconceptions surrounding Regulatory staff augmentation, which can lead to negative consequences for both the company and its employees. In this blog, we shall explore some of them and why it is important to approach staff augmentation in regulatory affairs with a clear understanding of its benefits and limitations. The following are the misconceptions:
Are high-interest rates, rising inflation, and unpredictable economic climate influencing your organization’s downturn? According to one of the reports, the medical science industry will necessitate seventy thousand (70,000) Regulatory roles over the next decade. Filling these positions has been and will continue to be a challenge for the industry.
So, what must pharmaceutical companies do to compete in today’s fast-paced and dynamic economic environment to fill in the gaps successfully?
Regulatory Affairs Staff augmentation is a trusted and proven staffing model that infuses the right talent at the right place at the right time into the life science organization’s flexible workforce plan.
Intended to provisionally enhance the internal team with expert resources cost-effectively and flexibly to meet the specific regulatory affairs staffing needs and solve the complex issues around urgent project deadlines and critical skillset shortages.
Outsourcing has become an increasingly common practice in the Pharma and Biotech industry more so in the area of regulatory affairs and Pharmacovigilance. Regulatory outsourcing has now become a norm as most companies are seeking partners to manage operational tasks including report publishing and submission publishing.